BioM MAxL and global healthcare company Daiichi Sankyo have launched a Golden Ticket to accelerate novel therapeutics and platform technologies in oncology, neuroscience, and ophthalmology. The winning team receives one year of free access to MAxL’s state-of-the-art lab and co-working space to advance its research.
MAxL's Golden Ticket program enables an outstanding founding team to advance its research work in the incubator's state-of-the-art laboratory and co-working space free of charge for one year. The team also benefits from a tailored mentoring and networking program - including valuable contacts to investors.
Daiichi Sankyo is actively involved in the selection process of the applicant teams and offers the winning start-up direct insights into the industry as well as access to its global network of experts and industry contacts.
Apply now if you are passionate about making a difference in the fields of:
Modality & Technology Area:
- RNA targeting therapeutics
- Cell & Gene therapy and associated technologies
- Chemical modalities and biologics designed to induce proximity
- Delivery technology to specific organs & cells
- Innovative technologies enabling the penetration of biologics into cells
Oncology Area:
- Innovative tumor-specific modalities including conditional activation and targeted delivery of biologics
- Distinctive techniques for identifying tumor-specific antigens and binders
- Chemical compounds exhibiting novel anti-cancer mechanisms
Specialty Medicine Area:
- Innovative research aimed at identifying disease-relevant targets through the use of patient tissue samples in the fields of central nervous system, cardiovascular, and ophthalmology
- Development of novel in vitro and in vivo models that accurately replicate human pathological mechanisms and conditions
The Prize:
As the winner, you’ll unlock a wealth of opportunities designed to propel your idea:
- 12-month rent-free incubator space in Martinsried, Munich
- Access to MAxL’s program to support commercial de-risking
- Mentoring & support from specialist business coaches
- Mentoring & support from Daiichi Sankyo’s drug discovery & development experts
- Access to BioM’s extensive industry and investor’s network
- Access to BioM’s vibrant ecosystem and events
How to apply:
Closing date for applications is 28 July 2025
If you’re working on ground-breaking solutions in these critical areas, we want to support you in turning your vision into reality. This is your chance to harness our world-class resources and take your innovation to the next level. Submit your application and once reviewed, shortlisted candidates will be invited to a pitching event following the submission deadline.
Please send your application until 28 July 2025 to Regina Abendroth: abendroth@bio-m.org.
Any questions? Please contact Regina Abendroth: abendroth@bio-m.org or Elisabeth Harbich: harbich@bio-m.org.
Find the application form and more information about the application here:
- Application form - BioM MAxL - Daiichi Sankyo Golden Ticket Program 2025
- Presentation for Applicants - BioM MAxL - Daiichi Sankyo Golden Ticket Program 2025
Selection process
All applications will be reviewed by the Daiichi Sankyo and MAxL selection committee
- Shortlisted candidates will be invited to a pitching event
- The winner startup will be announced in October 2025
- The selected winner startup shall be notified by MAxL and will enter into a direct contractual agreement with MAxL/BioM
- The successful candidate will move into MAxL until January 2026 the latest
About Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 30 countries/regions around the world. With a legacy of innovation since 1899, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our ca. 20,000 employees worldwide, we create innovative new and generic medicines. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
About MAxL- Munich Accelerator LifeSciences & Medicine
MAxL is BioM's unique pre-seed and start-up incubator based in Martinsried/Munich, the European hotspot for biotechnology.
MAxL supports selected Bavarian pre-seed and early-stage start-up teams from the fields of life sciences and healthtech by providing an exclusive high-end infrastructure on 900m2 in the immediate vicinity of BioM: shared and state-of-the-art laboratory space, co-working and community rooms, structured incubation and coaching programs, interdisciplinary co-creation space where life sciences meet AI and ML, and numerous networking opportunities. In addition, the incubator offers hands-on business building support and mentoring, training in bio-entrepreneurship and data science, and access to a vibrant start-up community and extensive BioM network for partnerships with pharma, big biotech, deeptech and other industry players as well as strategic partners, CROs and investors.